BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 1015538)

  • 1. Results of BCG adjuvant immunotherapy for melanoma of the head and neck.
    Eilber FR; Townsend CM; Morton DL
    Am J Surg; 1976 Oct; 132(4):476-9. PubMed ID: 1015538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma.
    Eilber FR; Morton DL; Holmes EC; Sparks FC; Ramming KP
    N Engl J Med; 1976 Jan; 294(5):237-40. PubMed ID: 1244548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma.
    Veronesi U; Adamus J; Aubert C; Bajetta E; Beretta G; Bonadonna G; Bufalino R; Cascinelli N; Cocconi G; Durand J; De Marsillac J; Ikonopisov RL; Kiss B; Lejeune F; MacKie R; Madej G; Mulder H; Mechl Z; Milton GW; Morabito A; Peter H; Priario J; Paul E; Rumke P; Sertoli R; Tomin R
    N Engl J Med; 1982 Oct; 307(15):913-6. PubMed ID: 7050717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary results of a randomized trial of adjuvant immunotherapy in patients with malignant melanoma who have lymph node metastases.
    Morton DL; Eilber FR; Holmes EC; Ramming KP
    Aust N Z J Surg; 1978 Feb; 48(1):49-52. PubMed ID: 276348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional control of head and neck melanoma with selective neck dissection.
    Geltzeiler M; Monroe M; Givi B; Vetto J; Andersen P; Gross N
    JAMA Otolaryngol Head Neck Surg; 2014 Nov; 140(11):1014-8. PubMed ID: 25275362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCG immunotherapy as a systemic adjunct to surgery in malignant melanoma.
    Morton DL; Eilber FR; Holmes EC; Sparks FC; Ramming K
    Med Clin North Am; 1976 May; 60(3):431-9. PubMed ID: 1271888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant BCG immunotherapy for stage I and II malignant melanoma.
    Silver HK; Ibrahim EM; Evers JA; Thomas JW; Murray RN; Spinelli JJ
    Can Med Assoc J; 1983 Jun; 128(11):1291-5. PubMed ID: 6342739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of survival and disease control in stage I melanoma of the head and neck.
    Ames FC; Sugarbaker EV; Ballantyne AJ
    Am J Surg; 1976 Oct; 132(4):484-91. PubMed ID: 1015539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intralymphatic and regional surgical adjuvant immunotherapy in high-risk melanoma of the extremities.
    Ariyan S; Kirkwood JM; Mitchell MS; Nordlund JJ; Lerner AB; Papac RJ
    Surgery; 1982 Sep; 92(3):459-63. PubMed ID: 7112396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Management of lymph nodes in head and neck melanoma: a retrospective study of 25 cases].
    Ricard AS; Majoufre-Lefebvre C; Delaunay M; Siberchicot F; Zwetyenga N
    Rev Stomatol Chir Maxillofac; 2007 Dec; 108(6):505-8. PubMed ID: 17900640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrence and survival after neck dissections in cutaneous head and neck melanoma.
    Andersen PS; Chakera AH; Thamsborg AK; Kølle SF; Schmidt G; Klyver H; Drzewiecki KT
    Dan Med J; 2014 Dec; 61(12):A4953. PubMed ID: 25441725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elective, therapeutic, and delayed lymph node dissection for malignant melanoma of the head and neck: analysis of 1444 patients from 1970 to 1998.
    Fisher SR
    Laryngoscope; 2002 Jan; 112(1):99-110. PubMed ID: 11802046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCG immunotherapy of malignant melanoma: summary of a seven-year experience.
    Morton DL; Eilber FR; Holmes EC; Hunt JS; Ketcham AS; Silverstein MJ; Sparks FC
    Ann Surg; 1974 Oct; 180(4):635-43. PubMed ID: 4412271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant immunotherapy with BCG in stage II malignant melanoma.
    Byrne MJ; Van Hazel G; Reynolds PM; Lemish WM; Holman CD
    J Surg Oncol; 1983 Jun; 23(2):114-6. PubMed ID: 6343725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent cutaneous melanoma of the head and neck.
    Zitsch RP; Roberts GD; Smith RB
    Otolaryngol Head Neck Surg; 1999 Mar; 120(3):391-3. PubMed ID: 10064644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective surgical management of cutaneous melanoma of the head and neck.
    Roses DF; Harris MN; Grunberger I; Gumport SL
    Ann Surg; 1980 Nov; 192(5):629-32. PubMed ID: 7436592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of low-dose technetium Tc 99m sulfur colloid to locate sentinel lymph nodes in melanoma of the head and neck: preliminary study.
    Rasgon BM
    Laryngoscope; 2001 Aug; 111(8):1366-72. PubMed ID: 11568570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival.
    McCulloch PB; Dent PB; Blajchman M; Muirhead WM; Price RA
    Can Med Assoc J; 1977 Jul; 117(1):33-6. PubMed ID: 861909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cutaneous malignant melanoma of the head and neck with intermediate tumor thickness: the role of elective lymph node dissection for clinical stage I].
    Wenzel S; Sagowski C; Neuber K; Kehrl W; Metternich FU
    Laryngorhinootologie; 2003 Jan; 82(1):19-24. PubMed ID: 12548460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCG immunotherapy in patients with malignant melanoma.
    Karakousis CP; Douglass HO; Yeracaris PM; Holyoke ED
    Arch Surg; 1976 Jun; 111(6):716-8. PubMed ID: 776125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.